The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Black Diamond Therapeutics, Inc(NASDAQ:BDTX)


Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutatio...
Founded: 2017
Full Time Employees: 58
CEO: David M. Epstein
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
Black Diamond Therapeutics Days Payable Outstanding ttm (DPO)
Black Diamond Therapeutics Op Cashflow Per Share ttm
Black Diamond Therapeutics Free Cashflow Per Share ttm
Black Diamond Therapeutics Cash Per Share ttm
Black Diamond Therapeutics (GAAP) P/E ratio ttm
Black Diamond Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.